Metrics as of 10/13/2026, 06:38 PM (Berlin time), refresh in progress.
Royalty Pharma Stock
Royalty Pharma plc
Company data
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Country
- United States
- CEO
- Pablo Legorreta
- Employees
- 100
- Market cap
- $25.1 B
- IPO
- 16/06/2020
Royalty Pharma plc operates within the Healthcare sector as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry. Based in New York, USA, the company is listed on the NASDAQ. Its portfolio consists of royalties on approximately 35 marketed therapies and 20…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Royalty Pharma stock: price history
1D
-2.1%
1W
+0.2%
1M
-3.5%
6M
+15.9%
YTD
+46.4%
1Y
+59.6%
2Y
+101.9%
5Y
+59.4%
10Y
–
Next earnings date
Next earnings date
04/11/2026 (in 18 days)
Volatility around earnings
~4% stronger price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vrange-breakout-v1.0 on 16/10/26. Not a buy or sell signal.Beta
What does this mean?
Range breakout
BullishThe price has broken out of a longer sideways range (support and resistance) to the upside or downside. In technical analysis, this is read as a signal that a new trend is starting in the breakout direction.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Royalty Pharma stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 07/10/2026.
Business model & megatrends
Robust business model that benefits noticeably from at least one megatrend.
1 more assignment (Enabler/Second row) Pro-only.
Royalty Pharma plc specializes in acquiring royalty rights to biopharmaceutical products. The company finances innovation by purchasing revenue shares from already-approved medications as well as drugs in development stages. Key focus areas span various therapeutic areas such as oncology, neurosciences, and infectious diseases. The majority of revenue is generated through royalties from its portfolio of marketed therapeutics, while other income streams play a minor role.
- Revenue model
- Transactional
- Recurring revenue
- High
- Pricing power
- Weak
- Moat
- None
- Moat type
- None
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about Royalty Pharma
Analyst assessment of Royalty Pharma
PRICE TARGET LOW
US$57.00
CONSENSUS
US$63.33
MEDIAN
US$66.00
PRICE TARGET HIGH
US$67.00
0
STRONG BUY
11
BUY
0
HOLD
0
SELL
0
STRONG SELL
11
TOTAL · Buy
As of: 07/10/2026
Royalty Pharma stock metrics
P/E
23.47
P/B
3.68
EV/EBITDA
19.36
RETURN ON EQUITY
0.3%
NET MARGIN
2.7%
DEBT/EQUITY
1.31
DIVIDEND YIELD
1.6%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
93.6%
FLOAT SHARES
415,017,498
AVG. DAILY VOLUME (30D)
3,206,987
Insider transactions (SEC)
Urist Marshall
Bassler Bonnie L
Urist Marshall
Hite Christopher
Hite Christopher
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -2.1%
Forums (Reddit)
Institutional holders
Dividends
Comparable stocks
Frequently asked questions about Royalty Pharma stock
What does Royalty Pharma do?
Royalty Pharma plc is a company in the Healthcare sector, Medical - Pharmaceuticals industry, headquartered in United States.
The CEO is Pablo Legorreta, the company employs around 100 people.
The IPO was on 16/06/2020; the stock trades on NASDAQ under the ticker RPRX.
What do analysts say about Royalty Pharma stock?
11 analysts rate the stock, the consensus is Buy (as of 07/10/2026).
The average price target is US$63.33, ranging from US$57.00 to US$67.00, with a median of US$66.00.
This is an external assessment, not a statement by Market Jury.
When does Royalty Pharma report next?
The next earnings date is 04/11/2026.
Around past earnings, price swings were roughly 4% stronger than usual.
Does Royalty Pharma pay a dividend?
Yes. The last dividend was US$0.24 per share, ex-date 14/08/2026, paid on 10/09/2026.
The dividend yield is 1.6% (as of 30/06/2026).
Which stocks are comparable to Royalty Pharma?
Comparable stocks include Corcept Therapeutics, Liquidia, Latigo Biotherapeutics, Helus Pharma, Eli Lilly and Company, Johnson & Johnson, AbbVie and Merck &.
How can I get Royalty Pharma stock analyzed?
Clicking "Analyze stock" lets five strategies assess Royalty Pharma against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.